Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3766

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3766). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3766 9)

This text appears to be the details of a medication, namely Duloxetine 30mg capsules. The text contains important information such as warnings to keep the medicine out of reach of children, details about the manufacturer, expiration date, and the composition of the capsules. Additionally, it provides information on how to report any potential side effects and the required storage temperature range for the medication.*

FDA Label Image

Figure1 (Duloxetine Fig1)

This is a comparison of the time to relapse in patients who were treated with a placebo versus those treated with Duloxetine. The graph shows the number of patients who experienced a relapse over time from randomization. The data appears to show that Duloxetine may have a longer time to relapse compared to the placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This text seems to be describing a medical study or clinical trial involving the use of Duloxetine at dosage of 60/120 mg once daily compared to a placebo. The data appears to include information on pain improvement from baseline. The study likely assesses the efficacy of Duloxetine in reducing pain.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This chart displays the proportion of patients experiencing a relapse over time from randomization. The two treatments compared are Placebo and Duloxetine. Time from randomization to relapse is measured in days. The graph indicates the percentage of patients with relapse for each treatment.*

FDA Label Image

Figure3 (Duloxetine Fig3)

This text provides information on the "Percentage of Patients Improved" based on different medication dosages. Duloxetine 60 mg BID shows improvement over Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. It also mentions the percent improvement in pain from baseline.*

FDA Label Image

Figure4 (Duloxetine Fig4)

Percentage of Patients Improved with different doses of Duloxetine (60 mg BID and 60 mg QD) compared to Placebo in terms of pain relief. The chart displays the percent improvement in pain from baseline for each treatment group.*

FDA Label Image

Figure5 (Duloxetine Fig5)

This text provides information on the percentage of patients improved based on different treatments, including Duloxetine 60mg Twice Daily, Duloxetine 60mg Once Daily, and Placebo. The chart shows the percentage improvement in pain from baseline for each treatment option. It helps to compare the effectiveness of the treatments in improving patient outcomes.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This evaluation provides the percentage of patients improved with Duloxetine 60 mg once daily compared to a placebo. The graph shows improvement in pain from baseline over time with 100% improvement noted.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This text seems to be related to medical treatment involving Duloxetine at a dose of 60/120 mg once daily for pain relief compared to a placebo. It also mentions a percentage improvement in pain from the baseline.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This is a comparison between a placebo and Duloxetine 60 mg once daily for pain relief. The text also shows the percentage improvement in pain from baseline using a BOCF (Baseline Observation Carried Forward) method.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.